Christopher Evans, M.D.

Christopher P. Evans, M.D.

Specialties

Cancer

Urologic Oncology

Urology

Robotic Surgery

Surgery - Robotic

Department

Urologic Surgery

Title

  • Professor

Reviews

To see if Christopher P. Evans is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2200
Sacramento, CA 95817
Driving Directions

Primary Phone:
916-734-2222

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

4501 X St.
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566

Additional Phone Numbers

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Evans' philosophy of care is to:

  • fully assess the patient's medical condition, including how it relates to family and social circumstances;
  • educate the patient fully about their disease process; and
  • include the patient in the decision-making process that best suits the outcomes they seek.

In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.

Clinical Interests

Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.

His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders.

Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.

Research/Academic Interests

Dr. Evans is the president of the Society of Urologic Oncology.

His research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor.

His laboratory work has also tested new agents and brought them from bench studies to animal models to clinical trials.

Division

Urology

Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center

Education

M.D., F.A.C.S., Dartmouth Medical School, Hanover NH 1986

B.A., University of Vermont, Burlington VT 1981

Internship: Madigan Army Medical Center, Tacoma WA 1986-1987

Residency

Surgery, UC San Francisco, San Francisco CA 1990-1991

Urology, UC San Francisco, San Francisco CA 1991-1995

Fellowships

University of California, San Francisco National Kidney Foundation Research Fellow, San Francisco CA 1993-1994

Urologic Oncology, University of Texas, M.D. Anderson Cancer Center, Houston TX 1995-1997

Board Certifications

American Board of Urology, 2009

American College of Surgeons, 2000

National Board of Medical Examiners, 1987

Professional Memberships

American Association for Cancer Research

American Association for the Advancement of Science

American Association of Genitourinary Surgeons

American College of Surgeons

American Society of Clinical Oncology, Past Chair, Genitourinary Cancer

American Urology Association

Association of Military Surgeons of the United States

European Association of Urology

Society for Basic Urologic Research

Society of Government Urologists

Southwest Oncology Group

Uniformed Services University

Honors and Awards

Recipient, The Platinum Award, European Association of Urology (EAU), 2018

American Association of Genitourinary Surgeons, Elected Membership, 2009

Western Section AUA nominee for the Gold Cystoscope Award, 2005

1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003

Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001

Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996

First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995

Recipient, American Association for Cancer Research Young Investigator Award, Basic and Clinical Aspects of Prostate Cancer, 1994

Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant, Molecular Biology, Aspen, CO, 1993

Recipient, Army Commendation Medal, 1990

Finalist, Army Science Conference Competition, 1990

Select Recent Publications

To view a detailed list of Dr. Evans' publications, please click here.

Evans, CP. Bipolar Androgen Therapy: An Intriguing Paradox. Lancet Oncology. 19(1):8-10.

Wang, HJ, Pochampalli, M, Wang, LY, Zou, JX, Li, PS, Hsu, SC, Wang, BJ, Huang, SH, Yang, P, Yang, JC, Chu, CY, Hsieh, CL, Sung, SY, Li, CF, Tepper, CG, Ann, DK, Gao, AC, Evans, CP, Izumiya, Y, Chuu, CP, Wang, WC, Chen, HW, Kung, HJ. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene.

Messing, EM, Tangen, CM, Lerner, SP, Sahasrabudhe, DM, Koppie, TM, Wood, DP, Mack, PC, Svatek, RS, Evans, CP, Hafez, KS, Culkin, DJ, Brand, TC, Karsh, LI, Holzbeierlein, JM, Wilson, SS, Wu, G, Plets, M, Vogelzang, NJ, Thompson, IM. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018;319(18):1880-1888.

Quigley, DA, Dang, HX, Zhao, SG, Lloyd, P, Aggarwal, R, Alumkal, JJ, Foye, A, Kothari, V, Perry, MD, Bailey, AM, Playdle, D, Barnard, TJ, Zhang, L, Zhang, J, Youngren, JF, Cieslik, MP, Parolia, A, Beer, TM, Thomas, G, Chi, KN, Gleave, M, Lack, NA, Zoubeidi, A, Reiter, RE, Rettig, MB, Witte, O, Ryan, CJ, Fong, L, Kim, W, Friedlander, T, Chou, J, Li, H, Das, R, Li, H, Moussavi-Baygi, R, Goodarzi, H, Gilbert, LA, Lara, PN, Evans, CP, Goldstein, TC, Stuart, JM, Tomlins, SA, Spratt, DE, Cheetham, RK, Cheng, DT, Farh, K, Gehring, JS, Hakenberg, J, Liao, A, Febbo, PG, Shon, J, Sickler, B, Batzoglou, S, Knudsen, KE, He, HH, Huang, J, Wyatt, AW, Dehm, SM, Ashworth, A, Chinnaiyan, AM, Maher, CA, Small, EJ, Feng, FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 174(3):758-769.e9.

Nguyen, HG, Conn, CS, Kye, Y, Xue, L, Forester, CM, Cowan, JE, Hsieh, AC, Cunningham, JT, Truillet, C, Tameire, F, Evans, MJ, Evans, CP, Yang, JC, Hann, B, Koumenis, C, Walter, P, Carroll, PR, Ruggero, D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018;10(439).

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinos EL, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat S, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology-Seminars and Original Investigations. 36(2):79.e11-79.e17.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute. 2017 Jun 29;109(12). https://doi.org/10.1093/jnci/djx118. 

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Oct:70(4):675-683.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 May 22;22(5):488-96.

Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 1;13:206. doi: 10.1186/s12916-015-0457-6. Review.